Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation
Ten feature sets classified cancer vs healthy on the primary paired-end dataset; mean over 10 outer folds.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
10 recorded evaluations, 20 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.
Results
Results are available, but no reviewed comparison panel is linked in this release.
All evaluations
10 evaluations · 20 results. Different protocols are not a single leaderboard.
Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation · Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples)
Sorted by AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
| Tested configuration | AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) | Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models) |
|---|---|---|
| Zeng et al. 2026 classifier: MethylationEvaluation | 0.986 (best in column) | 0.949 (best in column) |
| Zeng et al. 2026 classifier: Combined Motif + Methylation + Ratios (1%)Evaluation | 0.974 | 0.896 |
| Zeng et al. 2026 classifier: Combined All Features (1%)Evaluation | 0.97 | 0.86 |
| Zeng et al. 2026 classifier: Combined Ratios + Methylation (1%)Evaluation | 0.961 | 0.857 |
| Zeng et al. 2026 classifier: Combined Motif + Methylation (1%)Evaluation | 0.938 | 0.773 |
| Zeng et al. 2026 classifier: Combined All Features (5%)Evaluation | 0.932 | 0.789 |
| Zeng et al. 2026 classifier: End MotifsEvaluation | 0.93 | 0.826 |
| Zeng et al. 2026 classifier: Fragment RatioEvaluation | 0.923 | 0.795 |
| Zeng et al. 2026 classifier: Insert SizeEvaluation | 0.748 | 0.283 |
| Zeng et al. 2026 classifier: Nucleosome PeakEvaluation | 0.689 | 0.397 |
All 20 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: Zeng et al. 2026 classifier: Combined All Features (1%) | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.97 AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) unitless · higher Uncertainty: SD 0.0227978278651072. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceCombined All Features (1%) on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4a, row 2 'Combined All Features (1%)', column B 'mean_auc' |
| Configuration: Zeng et al. 2026 classifier: Combined All Features (1%) | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.86 Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models) fraction · higher Uncertainty: ± 0.0981509647480165 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceCombined All Features (1%) on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4b, row 2 'Combined All Features (1%)', column B 'mean_sens99' |
| Configuration: Zeng et al. 2026 classifier: Combined All Features (5%) | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.932 AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) unitless · higher Uncertainty: SD 0.0424929753478305. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceCombined All Features (5%) on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4a, row 3 'Combined All Features (5%)', column B 'mean_auc' |
| Configuration: Zeng et al. 2026 classifier: Combined All Features (5%) | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.789 Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models) fraction · higher Uncertainty: ± 0.107405582907328 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceCombined All Features (5%) on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4b, row 3 'Combined All Features (5%)', column B 'mean_sens99' |
| Configuration: Zeng et al. 2026 classifier: End Motifs | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.93 AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) unitless · higher Uncertainty: SD 0.0519161667413912. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceEnd Motifs on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4a, row 7 'End Motifs', column B 'mean_auc' |
| Configuration: Zeng et al. 2026 classifier: End Motifs | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.826 Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models) fraction · higher Uncertainty: ± 0.136261133071318 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceEnd Motifs on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4b, row 7 'End Motifs', column B 'mean_sens99' |
| Configuration: Zeng et al. 2026 classifier: Fragment Ratio | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.923 AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) unitless · higher Uncertainty: SD 0.0705965005812822. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceFragment Ratio on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4a, row 8 'Fragment Ratio', column B 'mean_auc' |
| Configuration: Zeng et al. 2026 classifier: Fragment Ratio | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.795 Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models) fraction · higher Uncertainty: ± 0.193024274189439 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceFragment Ratio on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4b, row 8 'Fragment Ratio', column B 'mean_sens99' |
| Configuration: Zeng et al. 2026 classifier: Insert Size | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.748 AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) unitless · higher Uncertainty: SD 0.0974579710205907. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceInsert Size on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4a, row 9 'Insert Size', column B 'mean_auc' |
| Configuration: Zeng et al. 2026 classifier: Insert Size | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.283 Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models) fraction · higher Uncertainty: ± 0.19494005154084 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceInsert Size on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4b, row 9 'Insert Size', column B 'mean_sens99' |
| Configuration: Zeng et al. 2026 classifier: Methylation | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.986 AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) unitless · higher Uncertainty: SD 0.0209780603284754. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceMethylation on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4a, row 10 'Methylation', column B 'mean_auc' |
| Configuration: Zeng et al. 2026 classifier: Methylation | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.949 Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models) fraction · higher Uncertainty: ± 0.0870136746761039 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceMethylation on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4b, row 10 'Methylation', column B 'mean_sens99' |
| Configuration: Zeng et al. 2026 classifier: Combined Motif + Methylation (1%) | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.938 AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) unitless · higher Uncertainty: SD 0.0401311333432108. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceCombined Motif + Methylation (1%) on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4a, row 4 'Combined Motif + Methylation (1%)', column B 'mean_auc' |
| Configuration: Zeng et al. 2026 classifier: Combined Motif + Methylation (1%) | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.773 Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models) fraction · higher Uncertainty: ± 0.14899523978531 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceCombined Motif + Methylation (1%) on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4b, row 4 'Combined Motif + Methylation (1%)', column B 'mean_sens99' |
| Configuration: Zeng et al. 2026 classifier: Combined Motif + Methylation + Ratios (1%) | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.974 AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) unitless · higher Uncertainty: SD 0.0242400530902103. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceCombined Motif + Methylation + Ratios (1%) on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4a, row 5 'Combined Motif + Methylation + Ratios (1%)', column B 'mean_auc' |
| Configuration: Zeng et al. 2026 classifier: Combined Motif + Methylation + Ratios (1%) | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.896 Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models) fraction · higher Uncertainty: ± 0.0857671794470052 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceCombined Motif + Methylation + Ratios (1%) on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4b, row 5 'Combined Motif + Methylation + Ratios (1%)', column B 'mean_sens99' |
| Configuration: Zeng et al. 2026 classifier: Nucleosome Peak | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.689 AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) unitless · higher Uncertainty: SD 0.1141088789247. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNucleosome Peak on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4a, row 11 'Nucleosome Peak', column B 'mean_auc' |
| Configuration: Zeng et al. 2026 classifier: Nucleosome Peak | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.397 Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models) fraction · higher Uncertainty: ± 0.143496781034909 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNucleosome Peak on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4b, row 11 'Nucleosome Peak', column B 'mean_sens99' |
| Configuration: Zeng et al. 2026 classifier: Combined Ratios + Methylation (1%) | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.961 AUROC (cancer vs healthy, primary PE dataset, mean over 10 fold models) unitless · higher Uncertainty: SD 0.0300613681834156. Figure 4 legend: error bars in a, c, e and g are ±1 s.d. across cross-validation folds (n = 10). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceCombined Ratios + Methylation (1%) on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4a, row 6 'Combined Ratios + Methylation (1%)', column B 'mean_auc' |
| Configuration: Zeng et al. 2026 classifier: Combined Ratios + Methylation (1%) | Protocol: Zeng et al. 2026 primary PE dataset: cancer vs healthy, nested cross-validation Dataset: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples) | 0.857 Sensitivity at 99% specificity (cancer vs healthy, primary PE dataset, mean over 10 fold models) fraction · higher Uncertainty: ± 0.0828537049838524 (type not stated). Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e. Methods P61 says error bars denote across-fold s.d. Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceCombined Ratios + Methylation (1%) on pe primary cv (Zeng et al. 2026) ctdnalit-20261011-zeng2026-protocol-pe-primary-cv Aggregation: Not reported A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection; Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Source Data Fig. 4, sheet Fig.4b, row 6 'Combined Ratios + Methylation (1%)', column B 'mean_sens99' |
Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.
Methods and evaluation design
Procedure, tasks and evaluated configurations
Recorded evaluations
Each evaluation records what was tested and under which conditions.
- Combined All Features (1%) on pe primary cv (Zeng et al. 2026)
- Combined All Features (5%) on pe primary cv (Zeng et al. 2026)
- End Motifs on pe primary cv (Zeng et al. 2026)
- Fragment Ratio on pe primary cv (Zeng et al. 2026)
- Insert Size on pe primary cv (Zeng et al. 2026)
- Methylation on pe primary cv (Zeng et al. 2026)
- Combined Motif + Methylation (1%) on pe primary cv (Zeng et al. 2026)
- Combined Motif + Methylation + Ratios (1%) on pe primary cv (Zeng et al. 2026)
- Nucleosome Peak on pe primary cv (Zeng et al. 2026)
- Combined Ratios + Methylation (1%) on pe primary cv (Zeng et al. 2026)
Baseline coverage
Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.
0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.
No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.
- Author-reported evaluations
- 10
Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.
Null control
Proposed control: requires review
Training-set class prior where supervised fitting is permitted
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Conventional reference
Proposed control: requires review
Regularised classifier on simple permitted features, or protocol's conventional reference
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)
Coverage is derived from release 2026-11-21-c8bea25e5abb. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.
Run instructions
No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
0 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|
No evidence rows match these filters. Choose another scope or clear the search.
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
2 source records and release history
- A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection · Original source · Nature Cancer, published online 2026-02-19; Europe PMC full-text JATS XML of PMC12948677
- Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Original source · 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file
Technical metadata and record identifiers
Technical metadata for this record is tracked under stable ID ctdnalit-20261011-zeng2026-protocol-pe-primary-cv.
Source locator: Results P29; Fig. 4a-b legend; Methods P59-P62
Related records
- uses data: Zeng et al. 2026 primary paired-end cfMeDIP-seq dataset (420 samples)
- assessment: Combined All Features (1%) on pe primary cv (Zeng et al. 2026)
- assessment: Combined All Features (5%) on pe primary cv (Zeng et al. 2026)
- assessment: End Motifs on pe primary cv (Zeng et al. 2026)
- assessment: Fragment Ratio on pe primary cv (Zeng et al. 2026)
- assessment: Insert Size on pe primary cv (Zeng et al. 2026)
- assessment: Methylation on pe primary cv (Zeng et al. 2026)
- assessment: Combined Motif + Methylation (1%) on pe primary cv (Zeng et al. 2026)
- assessment: Combined Motif + Methylation + Ratios (1%) on pe primary cv (Zeng et al. 2026)
- assessment: Nucleosome Peak on pe primary cv (Zeng et al. 2026)
- assessment: Combined Ratios + Methylation (1%) on pe primary cv (Zeng et al. 2026)
- assessed by: Select a plasma ctDNA fragmentomics detection workflow
- assessed by: Select a plasma ctDNA methylation detection workflow